Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2018 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.51%

Madrigal Pharmaceuticals reported a loss of $0.75 per share, which was in line with expectations, though no revenue figures were disclosed. The stock reacted negatively, declining by 0.51%. Investors may be concerned about the lack of guidance and the company's focus on clinical trials, which could impact future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.75	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious approach regarding future expectations. They emphasized the importance of their clinical pipeline.

Management did not provide specific revenue guidance for the upcoming quarter.

The focus remains on ongoing clinical trials and product development.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.51%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.51%

Key numbers

Management commentary